Tyrosine Kinase Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
{| class="wikitable" border="0" width="100%" style="text-align:center" | {| class="wikitable" border="0" width="100%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan=" | + | ! colspan="7" align="center"| Tyrosine Kinase Inhibitor [[Pharmacokinetics]] |
|- | |- | ||
! colspan="1" align="center"| | ! colspan="1" align="center"| | ||
Revision as of 15:47, 9 December 2010
| Tyrosine Kinase Inhibitor Pharmacokinetics | ||||||
|---|---|---|---|---|---|---|
| VEGFR & KIT Inhibitors | EGFR Inhibitors | PDGFR Inhibitor | ||||
| Parameter | Sunitinib (Sutent) | Sorafenib (Nexavar) | Erlotinib (Tarceva) | Gefitinib (Iressa) | Lapatinib (Tykerb) | Imatinib (Gleevec) |
| Tmax (hr) | 8 | 8.3 | 2.0 | 5.4 | 4 | Imatinib (Gleevec) |
| Cmax (ng/ml) | 24.6 | 460 | 69.6 | 130 | 115 | Imatinib (Gleevec) |
| Bioavailability (%) | Variable | 29-49 | 99 | 59 | Variable | Imatinib (Gleevec) |
| Protein Binding (%) | 95 | 99 | 93 | 90 | 99 | Imatinib (Gleevec) |
| T1/2 (hr) | 83 | 29 | 9.4 | 26.9 | 9.6 | Imatinib (Gleevec) |
| AUC (ng/ml/hr) | 1921 | 11040 | 20577 | 3850 | 1429 | Imatinib (Gleevec) |
| Dosage (mg) | 50 | 50 | 150 | 250 | 100 | Imatinib (Gleevec) |
| Metabolism | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic - (CYP3A4) | Hepatic - (CYP3A4) | Hepatic - (CYP3A4) | Imatinib (Gleevec) |
For references see: References
